Raymond DuBois to Clinical Trials as Topic
This is a "connection" page, showing publications Raymond DuBois has written about Clinical Trials as Topic.
Connection Strength
0.308
-
New, long-term insights from the Adenoma Prevention with Celecoxib Trial on a promising but troubled class of drugs. Cancer Prev Res (Phila). 2009 Apr; 2(4):285-7.
Score: 0.062
-
The COX-2 story: is any drug completely "safe?". Gastroenterology. 2006 Jan; 130(1):6.
Score: 0.050
-
Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol. 2005 Jan 10; 23(2):254-66.
Score: 0.046
-
Cyclooxygenase as a target in lung cancer. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 2):4266s-4269s.
Score: 0.044
-
COX-2 inhibition and colorectal cancer. Semin Oncol. 2004 Apr; 31(2 Suppl 7):12-21.
Score: 0.044
-
Cyclooxygenase-2: a therapeutic target. Annu Rev Med. 2002; 53:35-57.
Score: 0.038
-
Priorities in colorectal cancer research: recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups. J Clin Oncol. 2007 Jun 01; 25(16):2313-21.
Score: 0.014
-
Novel agents in the treatment of lung cancer: conference summary statement. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 2):4199s-4204s.
Score: 0.011